- Home
- STRO
STRO
Sutro Biopharma Inc.
as 11-15-2024 4:00pm EST
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 292.6M | IPO Year: | 2018 |
| Target Price: | $12.14 | AVG Volume (30 days): | 596.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.13 - $6.13 | Next Earning Date: | 11-13-2024 |
| Revenue: | $160,955,000 | Revenue Growth: | 230.90% |
| Revenue Growth (this year): | -56.17% | Revenue Growth (next year): | -3.61% |
Latest Sutro Biopharma Inc. News
STRO Breaking Stock News: Dive into STRO Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
4 days ago
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
GlobeNewswire
4 days ago
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
13 days ago
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
Clinical Trials Arena
13 days ago
Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children
MT Newswires
16 days ago
Sutro Biopharma Opens Enrollment for Luveltamab Tazevibulin Trial
GlobeNewswire
16 days ago
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
Simply Wall St.
a month ago
Sutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years ago
Compare STRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STRO Sutro Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.